Puma Biotechnology Inc (NASDAQ: PBYI) on Tuesday, soared 4.66% from the previous trading day, before settling in for the closing price of $3.43. Within the past 52 weeks, PBYI’s price has moved between $2.22 and $4.13.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of -21.77%. With a float of $37.28 million, this company’s outstanding shares have now reached $49.62 million.
Considering the fact that the conglomerate employs 172 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 72.4%, operating margin of 16.01%, and the pretax margin is 13.73%.
Puma Biotechnology Inc (PBYI) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Puma Biotechnology Inc is 24.89%, while institutional ownership is 53.40%. The most recent insider transaction that took place on Jun 13 ’25, was worth 36,720. In this transaction Director of this company sold 10,800 shares at a rate of $3.40, taking the stock ownership to the 43,550 shares. Before that another transaction happened on Jun 13 ’25, when Company’s Director sold 8,100 for $3.39, making the entire transaction worth $27,459. This insider now owns 94,958 shares in total.
Puma Biotechnology Inc (PBYI) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -21.77% per share during the next fiscal year.
Puma Biotechnology Inc (NASDAQ: PBYI) Trading Performance Indicators
Puma Biotechnology Inc (PBYI) is currently performing well based on its current performance indicators. A quick ratio of 1.43 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.77. Likewise, its price to free cash flow for the trailing twelve months is 5.72.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.77, a number that is poised to hit 0.09 in the next quarter and is forecasted to reach 0.23 in one year’s time.
Technical Analysis of Puma Biotechnology Inc (PBYI)
Compared to the last year’s volume of 0.43 million, its volume of 0.43 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 70.75%.
During the past 100 days, Puma Biotechnology Inc’s (PBYI) raw stochastic average was set at 81.53%, which indicates a significant increase from 78.85% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 50.77% in the past 14 days, which was lower than the 61.41% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.28, while its 200-day Moving Average is $3.04. Nevertheless, the first resistance level for the watch stands at $3.68 in the near term. At $3.77, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.89. If the price goes on to break the first support level at $3.47, it is likely to go to the next support level at $3.35. Should the price break the second support level, the third support level stands at $3.26.
Puma Biotechnology Inc (NASDAQ: PBYI) Key Stats
Market capitalization of the company is 178.20 million based on 49,631K outstanding shares. Right now, sales total 230,470 K and income totals 30,280 K. The company made 46,010 K in profit during its latest quarter, and 2,970 K in sales during its previous quarter.
